Azitra, Inc. (AZTR)
Oxford Ledge is still expanding full research coverage of AZTR. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Azitra develops genetically engineered bacterial therapies for skin diseases using proprietary microbial screening and artificial intelligence technologies.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Other material event; Financial statements and exhibits 2026-06-17
- 8-K Amendments to articles or bylaws; Shareholder vote results; Financial statements and exhibits 2026-06-16
- 8-K Other material event; Financial statements and exhibits 2026-06-04
- 8-K Other material event; Financial statements and exhibits 2026-05-27
- S-1 IPO / securities registration statement 2026-05-21
Source: SEC EDGAR.
Annual results
4 years of annual figures for AZTR, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $0 | -$11.0M | -$2.25 |
| 2024 | $7,500 | -$9.0M | -$15.70 |
| 2023 | $686,000 | -$11.3M | -$54.98 |
| 2022 | $284,000 | -$10.7M | -$12.74 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for AZTR. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open AZTR in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.